|
Accrued
Expenses, summarized by major category, as of March 31, 2023 and December 31, 2022 consist of the following:
Schedule
of Accrued Expenses
| |
|
March 31, 2023 |
|
|
December 31, 2022 |
|
| Payroll and incentives |
|
$ |
510 |
|
|
$ |
1,705 |
|
| General and administrative expenses |
|
|
186 |
|
|
|
455 |
|
| Research and development expenses |
|
|
95 |
|
|
|
130 |
|
| Deferred revenue * |
|
|
- |
|
|
|
721 |
|
| Other deferred liabilities ** |
|
|
- |
|
|
|
88 |
|
| Total |
|
$ |
791 |
|
|
$ |
3,099 |
|
| |
* |
At
December 31, 2022, the balance included $688 related to an exclusive research collaboration with BioNTech SE (the “BioNTech
Agreement”) and $33 was related to a feasibility study agreement with Genentech, Inc. (the “Genentech Agreement”).
(See Note 9 – Revenue Recognition, Collaboration Agreements and Other). |
| |
|
|
| |
** |
At
December 31, 2022, the balances of $88 was related to an award agreement with the Cystic Fibrosis Foundation (the “CFF Agreement).
(See Note 9 – Revenue Recognition, Collaboration Agreements and Other). |
|